Respiratory viral infections in the elderly

Antiviral Research

Volumn 44, Issue 2, 1999, Pages 79-102

  Treanor, John ^a   Falsey, Ann ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Elderly; Influenza; Parainfluenza; Respiratory syncytial; Respiratory viruses; Rhinovirus

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; PRASTERONE; QS 21; QUIL A; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIMANTADINE;

AGED; ANTIBODY TITER; CLINICAL TRIAL; EPIDEMIC; HUMAN; HUMAN RHINOVIRUS; INFLUENZA; INFLUENZA VACCINATION; PARAINFLUENZA VIRUS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; VACCINE PRODUCTION; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COMMON COLD; CORONAVIRUS INFECTIONS; HUMANS; INFLUENZA, HUMAN; MIDDLE AGED; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; VIRAL VACCINES;

HUMAN RHINOVIRUS SP.; RESPIRATORY SYNCYTIAL VIRUS; RHINOVIRUS; SYNCYTIAL VIRUS;

EID: 0032784889     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00062-5     Document Type: Review

References (210)

1. Agius G., Dindinaud G., Bigger R.J. et al. An epidemic of respiratory syncytial virus in the elderly: Clinical and serological findings. J. Med. Virol. 30:1990;117-127.
2. Angius G., Dindinaud G., Bigger R.J. et al. An epidemic of respiratory syncytial virus in the elderly: Clinical and serological findings. J. Med. Virol. 30:1990;117-127.
3. Anon Parainfluenza infections in the elderly 1976-1982. Can. Med. Assoc. J. 287(6405):1983;1619.
4. Arden N.H., Patriarca P.A., Fasano M.B. et al. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch. Intern. Med. 148:1988;865-868.
5. Arroyo J.C., Jordan A.W., Milligan L. Upper respiratory tract infection and serum antibody responses in nursing home patients. Infect. Cont. 16:1988;152-158.
6. Atkinson W.L., Arden N.H., Patriarca P.A., Leslie N., Lui K.-J., Gohd R. Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch. Intern. Med. 146:1986;1751-1756.
7. Atmar R.L., Bloom K., Keitel W., Couch R.B., Greenberg S.B. Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in heathy and asthmatic adults. Vaccine. 8:1990;217-224.
8. Barker W.H., Mullooly J.P. Impact of epidemic type A influenza in a defined adult population. Am. J. Epidemiol. 112(6):1980;798-813.
9. Barker W.H., Mullooly J.P. Pneumonia and influenza deaths during epidemics: implications for prevention. J. Am. Med. Assoc. 142:1982;85-89.
10. Barker W.H., Borisute H., Cox C. A study of the impact of influenza on the functional status of frail older people. Arch. Intern. Med. 158:1998;645-650.
11. Barrow G.I., Higgins P.G., Al-Nakib W., Smith A.P., Wenham R.B.M., Tyrrell D.A.J. The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers. Clin. Exp. Allergy. 20:1990;45-51.
12. Beem M.O. Acute respiratory illness in nursery school children: A longitudinal study of the occurrence of illness and respiratory viruses. Am. J. Epidemiol. 90:1969;30-44.
13. Belshe R.B., Anderson E.L., Walsh E.E. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J. Infect. Dis. 168(4):1993;1024-1029.
14. Belshe, R., Iacuzio, D., Mendelman, P., Wolff, M., 1997. Efficacy of a trivalent live attenuated intranasal influenza vaccine in children. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, CA.
15. Bennett N.M., Lewis B., Doniger A.S. et al. A coordinated, community wide program in Monroe County, New York, to increase influenza immunization rates in the elderly. Arch. Intern. Med. 154(15):1994;1741-1745.
16. Ben-Yehuda A., Danenberg H.D., Zakay-Rones Z., Gross D.J., Friedman G. The influence of sequential annual vaccination and of DHEA administration on the efficacy of the immune response to influenza vaccine in the elderly. Mech. Ageing Dev. 102(2-3):1998;299-306.
17. Betts R.F., Treanor J., Braman P., Bentley D., Dolin R. Antiviral agents to prevent or treat influenza in the elderly. J. Respir. Dis. 8:1987;S56-S59.
18. Betts, R.F., O'Brien. D., Menegus, M., et al., 1993. A comparison of the protective benefit of influenza (FLU) vaccine in reducing hospitalization of patients infected with FLU A or FLU B. Clin. Infect. Dis. 17(3), 573 (A257).
19. Blaine W.B., Luby J.P., Martin S.M. Severe illness with influenza B. Am. J. Med. 68:1980;181-189.
20. Buscho R.O., Saxtan D., Shultz P.S., Finch E., Mufson M.A. Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J. Infect. Dis. 137:1978;377-383.
21. Carilli A.D., Gohd R.S., Grodon W. A virologic study of chronic bronchitis. N. Engl. J. Med. 270:1964;123.
22. Cate T.R., Couch R.B., Parker D., Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev. Infect. Dis. 5(4):1983;737-747.
23. Cavallaro J.J., Monto A.S. Community-wide outbreak of infection with a 229E-like coronavirus in Tecumseh, Michigan. J. Infect. Dis. 122:1970;272-279.
24. CDC, 1998. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR 47 (RR-6), 1-26.
25. Chanock R.M., McIntosh D. Parainfluenza viruses. Fields B.N., Knipe D.M. Virology. 1:1990;963-988 Raven Press, New York.
26. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J. Clin. Microbiol. 23:1986;73-76.
27. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24(1):1986;157-160.
28. Clover R.D., Crawford S., Glezen W.P., Taber L.H., Matson C.C., Couch R.B. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inaactivated vaccines to A/Chile/83-like viruses. J. Infect. Dis. 163:1991;300-304.
29. Coles F.B., Balzano G.J., Morse D.L. An outbreak of influenza A(H3N2) in a well immunized nursing home population. J. Am. Geriatr. Soc. 40(6):1992;589-592.
30. Collins P.L., Hill M.G., Camargo E., Grosfeld H., Chanock R.M., Murphy B.R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. USA. 92(25):1995;11563-11567.
31. Cooney M.K., Fox J.P., Hall C.E. The Seattle virus watch. VI. Observations of infections with and illness due to parainfluenza, mumps, and respiratory syncytial viruses and Mycoplasma pneumoniae. Am. J. Epidemiol. 101:1975;532-551.
32. Crowe J.E. Jr., Bui P.T., London W.T. et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine. 12(8):1994;691-699.
33. Crowe J.E. Jr., Bui P.T., Siber G.R., Elkins W.R., Chanock R.M., Murphy B.R. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine. 13(9):1995;847-855.
34. Crowe J.E. Jr., Bui P.T., Firestone C.Y. et al. Live subgroup B respiratory synyctial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and non-human primates. J. Infect. Dis. 173:1996;829-839.
35. Daynes R.A., Araneo B.A. The development of effective vaccine adjuvants employing natural regulators of T-cell lymphokine production in vivo. Ann. N.Y. Acad. Sci. 730:1994;144-161.
36. Degelau J., Somani S.K., Cooper S.L., Guay D.R.P., Crossley K.B. Amantadine-resistant influenza A in a nursing facility. Arch. Intern. Med. 152:1992;390-392.
37. Dolin R., Reichman R.C., Madore H.P., Maynard R., Linton P.N., Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A in humans. N. Engl. J. Med. 307:1982;580-584.
38. Douglas R.G. Jr. Prophylaxis and treatment of influenza. N. Engl. J. Med. 322(7):1990;443-450.
39. Dowell S.F., Anderson L.J., Gary H.E. Jr. et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174(3):1996;456-562.
40. Drinka P.J., Gravenstein S., Schilling M., Krause P., Miller B.A., Shult P. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A: a comparison of two protocols. Arch. Intern. Med. 158:1998;2155-2159.
41. Eadie M.B., Stott E.J., Grist N.R. Virological studies in chronic bronchitis. Br. Med. J. 2:1966;671-673.
42. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D.J., Palmer P.S., Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 169(1):1994;68-76.
43. el Guink N., Kris R.M., Goodman-Snitkoff G., Small P.A.J., Mannino R.J. Intranasal immunization with proteoliposomes protects against influenza. Vaccine. 7(2):1989;147-151.
44. Englund J.A., Sullivan C.J., Jordan M.C. Respiratory syncytial virus infection in immunocompromised adults. Ann. Intern. Med. 109:1988;203-208.
45. Englund J.A., Anderson L.J., Rhame F.S. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J. Clin. Microbiol. 29(1):1991;115-119.
46. Fagan J.-Y., Chastre J. Severe exacerbations of COPD patients: the role of pulmonary infections. Sem. Respir. Infect. 11:1996;109-118.
47. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine. 14(13):1996;1214-1218.
48. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine. 15(10):1997;1130-1132.
49. Falsey A.R., Walsh E.E., Betts R.F. Serologic evidence of respiratory syncytial virus infection in nursing home patients. J. Infect. Dis. 162:1990;568-569.
50. Falsey A.R., Walsh E.E. Humoral immunity to respiratory syncytial virus infection in the elderly. J. Med. Virol. 36:1992;39-43.
51. Falsey A.R., Treanor J.J., Betts R.F., Walsh E.E. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc. 40:1992;115-119.
52. Falsey A.R., Treanor J.J., Betts R.F., Walsh E.E. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc. 40(2):1992;115-119.
53. Falsey A.R., Cunningham C.K., Barker W.H. et al. Respiratory syncytial virus and influenza A virus infections in the hospitalized elderly. J. Infect. Dis. 172:1995;389-394.
54. Falsey A.R., McCann R.M., Hall W.J. et al. Acute respiratory tract infection in daycare centers for older persons. J. Am. Geriatr. Soc. 43:1995;30-36.
55. Falsey A.R., McCann R.M., Hall W.J. et al. The 'common cold' in frail older persons: impact of rhinovirus and coronavirus in a senior daycare center. J. Am. Geriatr. Soc. 45(6):1997;706-711.
56. Falsey A.R., Walsh E.E. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J. Infect. Dis. 177(2):1998;463-466.
57. Fedson D.S., Wajda A., Nicol J.P., Hammond G.W., Kalser D.L., Roos L.L. Clinical effectivenss of influenza vaccination in Manitoba. J. Am. Med. Assoc. 270(16):1993;1956-1961.
58. Firestone C.Y., Whitehead S.S., Collins P.L., Murphy B.R., Crowe J.E. Jr. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature-sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology. 225(2):1996;419-422.
59. Fleet W.J., Couch R.B., Cate T.R., Knight V. Homologous and hetrologous resistance to rhinovirus common cold. Am. J. Epidemiol. 82:1965;185-196.
60. Fleming D.M., Cross K.W. Respiratory syncytial virus or influenza? Lancet. 342:1993;1507-1510.
61. Fransen H., Heigl Z., Wolontis S., Forsgren M., Svedmyr A. Infections with viruses in patients hospitalized with acute respiratory illness, Stockholm, 1963-1967. Scand. J. Infect. Dis. 1:1969;127-136.
62. Fulginiti V.A., Eller J.J., Joyner J.W., Askin P. Parainfluenza virus immunization. Am. J. Dis. Child. 114:1967;26-28.
63. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respriratory syncytial virus vaccine. Am. J. Epidemiol. 89:1969;435-448.
64. Galbraith A.W., Oxford J.S., Schild G.C. Protective effect of 1-adamantanamine hydrochloride on influenza A2 in the family environment. Lancet. 2:1969;1026-1028.
65. Gern J.E., Busse W.W. Association of rhinovirus infections with asthma. Clin. Microbiol. Rev. 12(1):1999;9-18.
66. Gladman J.R.F., Barer D., Venkatesan P. et al. The outcome of pneumonia in the elderly: a hospital survey. Clin. Rehab. 5:1991;201-205.
67. Glathe H., Bigl S., Grosche A. Comparison of humoral immune responses to trivalent influenza split vaccine in young, middle-aged and elderly people. Vaccine. 11(7):1993;702-705.
68. Glezen W.P., Loda F.A., Clyde W.A. Jr. et al. Epidemiologic patterns of acute lower respiratory disease of children in a pediatric group practice. J. Pediatr. 78(3):1971;397-406.
69. Glezen W.P. Serious morbidity and mortality associated with influenza epidemics. Epidemiol. Rev. 4:1982;24-44.
70. Gluck R., Mischler R., Finkel B., Que J.U., Scarpa B., Cryz S.J. Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet. 344(8916):1994;160-163.
71. Gorse G.J., Belshe R.B. Enhancement of anti-influenza A virus cytotoxicity following influenza A vaccination in older, chronically ill adults. J. Clin. Microbiol. 28:1990;2539-2550.
72. Gorse G.J., Belshe R.B., Munn N.J. Local and systemic antibody responses in high-risk adults given live attenuated and inactivated influenza A virus vaccines. J. Clin. Microbiol. 26:1988;911-918.
73. Gorse G.J., Belshe R.B., Munn N.J. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest. 100:1991;977-984.
74. Gorse G.J., Otto E.E., powers D.C., Chambers G.W., Eickhoff C.S., Newman F.K. Induction of mucosal antibodies by live attenuated and inactivated influenza vaccines in the chronically ill elderly. J. Infect. Dis. 173:1996;285-290.
75. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. J. Am. Med. Assoc. 270(16):1994;1956-1961.
76. Gravenstein S., Miller B.A. et al. Augmentation of influenza antibody response in elderly men by thymosin alpha one: a double-blind placebo-controlled clinical study. J. Am. Geriatr. Soc. 37:1989;1-8.
77. Gravenstein S., Drinka P., Duthie E.H. et al. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J. Am. Geriatr. Soc. 42(3):1994;245-251.
78. Greenberg S.B. Viral pneumonia. Infect. Dis. Clin. North Am. 5(3):1991;603-621.
79. Gross P.A., Quinnan G.V., Weksler M.E., Gaerlan P.F., Cenning C.R. Immunization of elderly people with high doses of influenza vaccine. J. Am. Geriatr. Soc. 36:1988;209-212.
80. Gross P.A., Rodstein M., LaMontagne J.R. et al. Epidemiology of acute respiratory illness during an influenza outbreak in a nursing home: a prospective study. Arch. Intern. Med. 148:1988;559-561.
81. Gross P.A., Quinnan G.V., Weksler M.E., Setia U., Douglas R.G. Jr. Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine. 7:1989;303.
82. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., Levandowski R.A. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann. Intern. Med. 123:1995;518-527.
83. Gruber W.C., Campbell P.W., Thompson J.M., Reed G.W., Roberts B., Wright P.F. Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: results of a 3-year study. J. Infect. Dis. 169:1994;241-247.
84. Gwaltney J.M. Jr. Combined antiviral and antimediator treatment of rhinovirus colds. J. Infect. Dis. 166(4):1992;776-782.
85. Gwaltney J.M. Jr., Hendley J.O., Simon G., Jordan W.S. Jr. Rhinovirus infections in an industrial population. I. the occurrence of illness. N. Engl. J. Med. 275:1966;1261-1268.
86. Gwaltney J.M. Jr., Hendley J.O., Simon G., Jordan W.S. Jr. Rhinovirus infections in an industrialized population II characteristics of illness and antibody response. J. Am. Med. Assoc. 202(6):1967;158-164.
87. Gwaltney J.M. Jr., Phillips C.D., Miller R.D., Riker D.K. Computed tomographic study of the common cold. N. Engl. J. Med. 330(1):1994;25-30.
88. Hall C.G., Geiman J.M., Biggar R., Kotok D., Hogan P., Douglas R.G. Jr. Respiratory syncytial virus infections within families. N. Engl. J. Med. 294:1976;414-419.
89. Hall W.J., Hall C.B., Speers D.M. Respiratory syncytial virus infection in adults. Ann. Intern. Med. 88:1978;203-205.
90. Halperin S.A., Eggleston P.A., Hendley J.O., Suratt P.M., Groschel D.H.M., Gwaltney J.M. Jr. Pathogenesis of lower respiratory tract symptoms in experimental rhinovirus infection. Am. Rev. Respir. Dis. 128:1983;806-810.
91. Halperin S.A., Eggleston P.A., Beasley P. et al. Exacerbations of asthma in adults during experimental rhinovirus infection. Am. Rev. Respir. Dis. 132:1985;976-980.
92. Hamre D., Beem M. Virologic studies of acute respiratory disease in young adults. V. Coronavirus 229E infections during six years of surveillance. Am. J. Epidemiol. 96:1972;94-106.
93. Hamre D., Procknow J.J. A new virus isolated from the human respiratory tract. Proc. Soc. Exp. Biol. Med. 121:1966;190-193.
94. Harrington R.D., Hooton R.D., Hackman R.C. et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J. Infect. Dis. 165:1992;987-993.
95. Hayden F.G., Monto A.S. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob. Agents Chemother. 29(2):1986;339-341.
96. Hayden F.G., Belshe R.B., Clover R.D., Hay A.J., Oakes M.G., Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med. 321:1989;1696-1702.
97. Hayden F.G., Andries K., Jannssen P.A.J. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob. Agents Chemother. 36(4):1992;727-732.
98. Hayden F.G., Treanor J.J., Betts R.F., Lobo M., Esinhart J.D., Hussey E.K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. J. Am. Med. Assoc. 275:1996;295-299.
99. Hayden F.G., Osterhaus A.D.M.E., Treanor J.J. et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N. Engl. J. Med. 337(13):1997;874-880.
100. Hayden, F.G., Treanor, J.J., Lobo, M., et al., 1999. Randomized, double-blind studies of the oral neuramindase inhibitor GS4104 (Ro64-0796) in experimental human influenza. J. Am. Med. Assoc. (in press).
101. Hayden, F.G., Hassman, H.A., Coats, T., Menendez, R., Bock, T., 1999. Pleconaril treatment shortens the duration of piconavirus respiratory illness in adults. Abstract LB-3. In: Thirty-ninth Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1999.
102. Hendley J.O., Gwaltney J.M., Jordan W.S. Jr. Rhinovirus infections in an industrial population. IV. infections within families of employeees during two fall peaks of respiratory illness. Am. J. Epidemiol. 89(2):1969;184-196.
103. Hendley J.O., Fishburne H.B., Gwaltney J.M. Jr. Coronavirus infections in working adults. Eight year study with 229E and OC43. Am. Rev. Respir. Dis. 105:1972;805-811.
104. Hertz M.I., Englund J.A., Snover D., Bitterman P.B., McGlave P.B. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine. 68(5):1989;269-281.
105. Higgins P.G., Phillpotts R.J., Scott G.M., Wallace J., Bernhardt L.L., Tyrrell D.A.J. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob. Agents Chemother. 24:1983;713-715.
106. Horn M.E.C., Reed S.E., Taylor P. Role of viruses and bacteria in acute wheezy bronchitis in childhood. Arch. Dis. Child. 54:1979;587-592.
107. Houck P., Hemphill M., SlCroix S., Hirsh D., Cox N. Amantadine-resistant influenza A in nursing homes: identification of a resistant virus prior to drug use. Arch. Intern. Med. 155:1995;533-537.
108. Hsu K.-H., Lubeck M.D., Davis A.R. et al. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J. Infect. Dis. 199:1992;769-775.
109. Hsu K.H., Lubeck M.D., Bhat B.M. et al. Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Vaccine. 12(7):1994;607-612.
110. Hudgel D.W., Lanston L., Selner J.C., McIntosh K. Viral and bacterial infections in adults with chronic asthma. Am. Rev. Respir. Dis. 120:1979;393-397.
111. Kaji M., Kaji Y., Kaji M. et al. Phase I clinical tests of influenza MDP-virosome vaccine (KD-5382). Vaccine. 10(10):1992;637-663.
112. Karron R.A., Wright P.F., Hall S.L. et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J. Infect. Dis. 171:1995;1107-1114.
113. Karron R.A., Wright P.F., Newman F.K. et al. A live human parainfluenza virus type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J. Infect. Dis. 172:1995;1445-1450.
114. Kaye H.S., Dowdle W.R. Seroepidemiologic survey of coronavirus (strain 229E) infections in a population of children. Am. J. Epidemiol. 101:1975;238-244.
115. Kaye H.S., Marsh H.B., Dowdle W.R. Seroepidemiologic survey of coronavirus (strain OC43) related infections in a children's population. Am. J. Epidemiol. 94:1971;43-49.
116. Keitel W.A., Couch R.B., Cate T.R. et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J. Clin. Microbiol. 32(10):1994;2468-2473.
117. Keyser, L.A., Karl, M., Nafziger, A.N., Bertino, J.S., Jr., 1998. Comparison of adverse events (AEs) of amantadine (AM) and rimantadine (RM) used as sequential prophylaxis of influenza A (FLU) in elderly nursing home residents. 38th ICAAC, San Francisco, CA: American Society of Microbiology.
118. Kim H.W., Arrobio J.O., Brandt C.D. et al. Safety and antigenicity of temperature-sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics. 52:1973;56-63.
119. Lambert H.P., Stern H. Infective factors in exacerbations of bronchitis and asthma. Br. Med. J. 3:1972;323-327.
120. LaMontagne J.R., Noble G.R., Quinnan G.V. et al. Summary of clinical trials of inactivated influenza vaccine - 1978. Rev. Infect. Dis. 5(4):1983;723-736.
121. Lovgren K., Kaberg H., Morein B. An experimental influenza subunit vaccine (ISCOM): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clin. Exp. Immunol. 82(3):1990;435-439.
122. Maassab H.F., DeBorde D.C. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine. 3:1985;335-369.
123. MacFarlane J.T., Colville A., Guion A., MacFarlane R.M., Rose D.H. Prospective study of aetiology and outcome of adults lower respiratory tract infections in the community. Lancet. 34:1993;511-514.
124. Macnaughton M.R. Occurrence and frequency of coronavirus infections in humans as determined by enzyme linked immunosorbent assay. Infect. Immunol. 38:1982;419-423.
125. Marrie T.J., Peeling R.W., Fine M.J., singer D.E., Coley C.M., Kappor W.N. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am. J. Med. 101:1996;508-515.
126. Martin M.A., Block M.J., Peallen M.A., Wenzel R.P. Respiratory syncytial virus infections in adult bone marrow transplant recipients. Lancet. i:1988;1341-1343.
127. Martin J.T. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals. 25(2):1997;209-213.
128. Mast E.E., Harman M.W., Gravenstein S. et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am. J. Epidemiol. 134(9):1991;988-997.
129. Mathur U., Bentley D.W., Hall C.B. Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill. Ann. Intern. Med. 93:1980;49-52.
130. McKay E., Higgins P., Tyrrell D., Pringle C. Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers. J. Med. Virol. 25:1988;411.
131. McNamara M.J., Phillips I.A., Williams O.B. Viral and Mycoplasma pneumoniae infections in exacerbations of chronic lung disease. Am. Rev. Respir. Dis. 100:1969;19-24.
132. Meiklejohn G., Eickhoff T.C., Graves P.I.J. Antigenic drift and efficacy of influenza virus vaccines, 1976-1977. J. Infect. Dis. 138(5):1978;618-624.
133. Meiklejohn G. Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982. J. Infect. Dis. 148(5):1983;775-783.
134. Minor T.E., Dick E.C., DeMeo A.N., Ouellette J.J., Cohen M., Reed C.E. Viruses as precipitants of asthmatic attacks in children. J. Am. Med. Assoc. 21:1974;292-298.
135. Minor T.E., Dick E.C., Baker J.W., Ouellette J.J., Cohen M., Reed C.E. Rhinovirus and influenza type A infections as precipitants of asthma. Am. Rev. Respir. Dis. 113:1976;149-153.
136. Minutello M., Senatore F., Cecchinelli G. et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine. 17(2):1999;99-104.
137. Miyazaki C., Nakayama M., Tanaka Y. et al. Immunization of institutionalized asthmatic children and patients with psychomotor retardation using live attenuated cold-adapted reassortment influenza A H1N1, H3N2, and B vaccines. Vaccine. 11(8):1993;853-858.
138. Monto A.S., Lim S.K. The Tecumseh study of respiratory illness. VI. Frequency of and relationship between outbreaks of coronavirus infection. J. Infect. Dis. 129:1974;271-276.
139. Monto A.S., Sullivan K.M. Acute respiratory illness in the community: frequency of illness and the agents involved. Epidemiol. Infect. 110:1993;145-160.
140. Monto A.S., Ohmit S.E., Hornbuckle K., Pearce C.L. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob. Agents Chemother. 39:1995;2224-2228.
141. Monto A.S., Robinson D.P., Herlocher M.L., Hinson J.M. Jr., Elliot M.J., Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. J. Am. Med. Assoc. 282(1):1999;31-35.
142. Monto A.S. Coronaviruses. Evans A.S. Viral Infections of Humans. 1997;211-227 Plenum Publishing, New York.
143. Mufson M.A., Chang V., Gill V. et al. The role of viruses, Mycoplasma and bacteria in acute pneumonia in civilian adults. Am. J. Epidemiol. 86:1967;526-587.
144. Mufson M.A., Mocega H.E., Krause H.E. Acquisition of parainfluenza 3 virus infection by hospitalized children. I. Frequencies, rates, and temporal data. J. Infect. Dis. 128:1973;141-147.
145. Murphy B.R. Use of live, attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults, and elderly adults. Infect. Dis. Clin. Pract. 2:1993;176-181.
146. Neuzil K.M., Johnson J.E., Tang Y.W. et al. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine. 15(5):1997;525-532.
147. Nichol K.L., Margolis K.L., Wuorenma J., Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 331(12):1994;778-784.
148. Nichol K.L., Mendelman P.M., Mallon K.P. et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. J. Am. Med. Assoc. 282(2):1999;137-144.
149. Nicholson K.G. Impact of influenza and respiratory syncytial virus on mortality in England and Wales from Jaunary to December 1990. Epidemiol. Infect. 116:1975;51-63.
150. Nicholson K.G., Baker D.J., Farquhar A., Hurd D., Kent J., Smith S.H. Acute upper respiratory tract viral illness and influenza immunization in homes for the elderly. Epidemiol. Infect. 105(3):1990;609-618.
151. Nicholson K.G., Baker D.J., Chakraverty P. et al. Immunogenicity of inactivated influenza vaccine in residential homes for elderly people. Age Ageing. 21:1992;182-188.
152. Nicholson K.G., Kent J., Hammersley V., Cancio E. Risk factors for lower respiratory complications of rhinovirus infections in elderly people living in the community: prospective cohort study. Br. Med. J. 313(7065):1996;1119-1123.
153. Nicholson K.G., Kent J., Hammersley V., Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. Br. Med. J. 315(7115):1997;1060-1064.
154. Osterweil D., Norman D. An outbreak of an influenza-like illness in a nursing home. J. Am. Geriatr. Soc. 38:1990;659-662.
155. Palache A.M., Beyer W.E.P., Sprenger M.J.W. et al. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-respones study in elderly nursing home residents and young volunteers. Vaccine. 11(1):1993;3-9.
156. Parrott R.H., Kim H.W., Arrobio J.O. Epidemiology of respiratory syncytial virus infection in Washington, DC. Am. J. Epidemiol. 98:1973;289-300.
157. Perrotta D.M., Decker M., Glezen W.P. Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. Am. J. Epidemiol. 122(3):1985;468-476.
158. Pitkaranta A., Arruda E., Malmberg H., Hayden F.G. Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. J. Clin. Microbiol. 35(7):1997;1791-1793.
159. Powers D.C., Belshe R.B. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza vaccine. J. Infect. Dis. 197:1993;584-592.
160. Powers D.C., Sears S.D., Murphy B.R., Thuman B., Clements M.L. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J. Clin. Microbiol. 27:1989;2666-2671.
161. Powers D.C., Fries L.F., Murphy B.R., Thumar J.B., Clements M.L. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J. Clin. Microbiol. 29:1991;498-505.
162. Powers D.C., Murphy B.R., Fries L., Adler W.H., Clements M.L. Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J. Am. Geriatr. Soc. 40:1992;163-167.
163. Powers D.C. Effect of age on serum immunoglobulin G subclass antibody responses to inactivated influenza virus vaccine. J. Med. Virol. 43(1):1994;57-61.
164. Powers D.C. Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults. Mech. Aging Dev. 93(1-3):1997;179-188.
165. Pozzetto B., Odelin M.F., Bienvenu J., Defayolle M., Aymard M. Is there a relationship between malnutrition, inflammation, and post-vaccinal antibody response to influenza viruses in the elderly? J. Med. Virol. 41(1):1993;39-43.
166. Pringle C.R., Filipiuk A.H., Robinson B.S., Watt P.J., Higgins P., Tyrrell D.A.J. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine. 11(4):1993;473-478.
167. Provinciali M., Di Stefano G., Colombo M. et al. Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects. Mech. Ageing Dev. 77(2):1994;75-82.
168. Quinnan G.V., Schooley R., Dolin R., Ennis F.A., Gross P., Gwaltney J.M. Jr. Serologic respones and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev. Infect. Dis. 5(4):1983;748-757.
169. MIST, 1998. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 352, 1877-1881.
170. Rao S.S., Hendley J.O., Hayden F.G., Gwaltney J.M. Symptom expression in natural and experimental rhinovirus colds. Am. J. Rhinol. 9:1995;49-52.
171. Ray R., Brown V.E., Compans R.W. Glycoproteins of human parainfluenza virus type 3: characterization and evaluation as a subunit vaccine. J. Infect. Dis. 152(6):1985;1219-1229.
172. Ray R., Glaze B.J., Compans R.W. The role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response. J. Virol. 62:1988;783-787.
173. Reed S.E. The behavior of recent isolates of human respiratory coronavirus in vitro in volunteers: Evidence of heterogeneity among 229E-related strains. J. Med. Virol. 13:1984;179-192.
174. Remarque E.J., van Beek W.C., Ligthart G.J. et al. Improvement of the immunoglobulin subclass response to influenza vaccine in elderly nursing-home residents by the use of high dose vaccines. Vaccine. 11(6):1993;649-654.
175. Renegar K.B., Small P.A.J. Passive transfer of local immunity to influenza virus by IgA antibody. J. Immunol. 146(6):1991;1972-1978.
176. Ruben F.L. Prevention and control of influenza: role of vaccine. Am. J. Med. 82(6A):1987;31-33.
177. Schilling M., Povinelli L., Krause P. et al. Efficacy of zanamivir for
178. Simonsen L., Clarke M.J., Williamson D.W., Stroup D.F., Arden N.H., Schonberger L.B. The impact of influenza epidemics on mortality: introducing a severity index. Am. J. Pub. Health. 87:1997;1944-1950.
179. Smith C.B., Kanner R.E., Golden C.A., Klauber M.R., Renzetti A.D.J. Effect of viral infections on pulmonary function in patients with chronic obstructive pulmonary diseases. J. Infect. Dis. 141:1985;271-280.
180. Soo W. Adverse effects of rimantadine: summary from clinical trials. J. Respir. Dis. 10:1989;S26-S31.
181. Sorvillo F.J., Huie S.F., Strassburg M.A., Butsumyo A., Shandera W.X., Fannin S.L. An outbreak of respiratory syncytial virsu pneumonia in a nursing home for the elderly. J. Infect. 9:1984;252-256.
182. Spriggs M.K., Murphy B.R., Prince G.A., Olmsted R.A., Collins P.L. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia virus: contributions of the individual proteins to host immunity. J. Virol. 61:1987;3416-3423.
183. Stanek J., Heinz F. On the epidemiology and etiology of pneumonia in adults. J. Hyg. Epidemiol. Microbiol. Immunol. 32:1988;31-38.
184. Stenhouse A.C. Rhinovirus infection in acute exacerbation of chronic bronchitis: a controlled prospective study. Br. Med. J. 3:1967;461.
185. Sullivan K.M., Monto A.S., Longini I.M. Estimates of the US health impact of influenza. Am. J. Pub. Health. 83(12):1993;1712-1716.
186. Sundquist B., Lovgren K., Hoglund S., Morein B. Influenza virus ISCOMs: biochemical characterization. Vaccine. 6:1988;44-48.
187. Teichtahl H., Buckmaster N., Pertnikovs E. The incidence of respiratory tract infection in adults requiring hospitalization for asthma. Chest. 112(3):1997;591-596.
188. Tominack R.L., Hayden F.G. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect. Dis. Clin. North Am. 1(2):1987;459-478.
189. Treanor J.J., Betts R.F. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccine. 16:1998;1756-1760.
190. Treanor J.J., Mattison H.R., Dumyati G. et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann. Intern. Med. 117(8):1992;625-633.
191. Treanor J., Dumyati G., O'Brien D. et al. Evaluation of cold-adapted, reassortant influenza B virus vaccines in elderly and chronically ill adults. J. Infect. Dis. 169(2):1994;402-407.
192. Treanor J.J., Betts R.F., Smith G.E. et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J. Infect. Dis. 173(6):1996;1467-1470.
193. Treanor, J.J., Betts, R.F., Kotloff, K., et al., 1999. Efficacy of trivalent, live, cold-adapted influenza vaccine (CAIV-T) in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine (in press).
194. Turner B.W., Cail W.S., Hendley J.O. et al. Physiologic abnormalities in the paranasal sinuses during experimental rhinovirus colds. J. Allergy Clin. Immunol. 90(3 pt. 2):1992;474-478.
195. Turner R.B., Wecker M.T., Pohl G. et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection. J. Am. Med. Assoc. 281(19):1999;1797-1804.
196. Van Voris L.P., Betts R.F., Hayden F.G., Christmas W.A., Douglas R.G. Jr. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. J. Am. Med. Assoc. 245(11):1981;1128-1131.
197. Varghese J.N., Laver W.G., Colman P.M. Structure of the influenza glycoprotein antigen neuraminidase at 2.9A resolution. Nature. 303:1983;35-40.
198. Vikerfors T., Grandien M., Olan P. Respiratory syncytial virus infections in adults. Am. Rev. Respir. Dis. 136:1987;561-564.
199. Vikerfors T., Grandien M., Johansson M., Pettersson C.-A. Detection of an immunoglobulin M response in the elderly for early diagnosis of respiratory syncytial virus infection. J. Clin. Microbiol. 26:1988;808-811.
200. von Itzstein M., Wu W.-Y., Kok G.B. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 363:1993;418-423.
201. Wald E.R., Guerra N., Byers C. Upper respiratory tract infections in young children: duration of and frequency of complications. Pediatrics. 87:1991;129-133.
202. Wald T.G., Shult P., Krause P., Miller B.A., Drinka P., Gravenstein S. A rhinovirus outbreak among residents of a long-term care facility. Ann. Intern. Med. 123(8):1995;588-593.
203. Walker J.B., Hussey E.K., Treanor J.J., Montalvo A. Jr., Hayden F.G. Effects of the neuraminidase inhibitor Zanamivir on otologic manifestations of experimental human influenza. J. Infect. Dis. 176(6):1997;1417-1422.
204. Weibel, R.E., Stokes, J., Mascoli, C.C., et al., 1967. Respiratory virus vaccines: VII. Field evaluation of respriatory syncytial, parainfluenza 1, 2, 3, and Mycoplasma pneumoniae vaccines, 1965 to 1966. Am. Rev. Respir. Dis. 96, 724-739.
205. Wertz G.W., Stott E.J., Young K.K., Anderson K., Ball L.A. Expression of the fusion protein of human respiratory sysncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J. Virol. 61(2):1987;293-301.
206. Whimbey E., Champlin R.E., Englund J.A. et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 16:1995;393-399.
207. Woods J.M., Bethell R.C., Coates J.A.V. et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37(7):1993;1473-1479.
208. Wright P.F., Belshe R.B., Kim H.W., Van Voris L.P., Chanock R.M. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect. Immun. 37:1982;397-400.
209. Younkin S.W., Betts R.F., Roth F.K., Douglas R.G. Jr. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob. Agents Chemother. 23(4):1983;577-582.
210. Zaroukian M.H., Kashyap G.H., Wentworth B. Case report: respiratory syncytial virus infection - a cause of respiratory distress syndrome and pneumonia in adults. Am. J. Med. Sci. 295:1988;218-222.